DK2714912T3 - POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA - Google Patents

POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA Download PDF

Info

Publication number
DK2714912T3
DK2714912T3 DK12729396.7T DK12729396T DK2714912T3 DK 2714912 T3 DK2714912 T3 DK 2714912T3 DK 12729396 T DK12729396 T DK 12729396T DK 2714912 T3 DK2714912 T3 DK 2714912T3
Authority
DK
Denmark
Prior art keywords
gram
gene
positive bacterium
promoter
seq
Prior art date
Application number
DK12729396.7T
Other languages
Danish (da)
English (en)
Inventor
Klaas Vandenbroucke
Huynegem Karolien Van
Lothar Steidler
Original Assignee
Intrexon Actobiotics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics Nv filed Critical Intrexon Actobiotics Nv
Application granted granted Critical
Publication of DK2714912T3 publication Critical patent/DK2714912T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
DK12729396.7T 2011-06-01 2012-06-01 POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA DK2714912T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11168495 2011-06-01
EP11173588 2011-07-12
PCT/EP2012/060431 WO2012164083A1 (en) 2011-06-01 2012-06-01 Polycistronic expression system for bacteria

Publications (1)

Publication Number Publication Date
DK2714912T3 true DK2714912T3 (en) 2018-08-13

Family

ID=46354175

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12729396.7T DK2714912T3 (en) 2011-06-01 2012-06-01 POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA

Country Status (13)

Country Link
US (3) US9920324B2 (enExample)
EP (2) EP2714912B1 (enExample)
JP (3) JP6175428B2 (enExample)
KR (1) KR102066292B1 (enExample)
CN (2) CN107267546B (enExample)
AU (2) AU2012264589B2 (enExample)
BR (1) BR112013030824A8 (enExample)
CA (2) CA3136084A1 (enExample)
DK (1) DK2714912T3 (enExample)
ES (1) ES2676877T3 (enExample)
HU (1) HUE039577T2 (enExample)
RU (2) RU2766157C2 (enExample)
WO (1) WO2012164083A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920324B2 (en) 2011-06-01 2018-03-20 Intrexon Actobiotics Nv Polycistronic expression system for bacteria
US9593339B1 (en) * 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
JPWO2015022798A1 (ja) * 2013-08-13 2017-03-02 学校法人北里研究所 新規テルペノイド化合物およびその製造方法
KR20170088866A (ko) * 2014-12-03 2017-08-02 가부시키가이샤 아네로파마·사이엔스 공발현 플라스미드
CA2971520C (en) 2014-12-23 2024-04-09 Ilya Pharma Ab Methods for wound healing
CA2984701C (en) * 2015-05-10 2023-09-26 Ventana Medical Systems, Inc. Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3402499B1 (en) 2016-01-14 2021-07-21 Intrexon Actobiotics NV Compositions and methods for the treatment of type 1 diabetes
CN109843320A (zh) 2016-09-02 2019-06-04 英特瑞克斯顿阿克图比奥帝克斯有限公司 稳定表达il-10和胰岛素的遗传修饰的细菌
RU2762940C2 (ru) 2016-09-13 2021-12-24 Интрексон Актобиотикс Н.В. Мукоадгезивный микроорганизм
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
GB201906775D0 (en) * 2019-05-14 2019-06-26 Res & Innovation Uk Synthetic genome
CN114761028A (zh) 2019-09-27 2022-07-15 英特瑞克斯顿阿克图比奥帝克斯有限公司 乳糜泻的治疗
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB227835A (en) 1924-01-15 1925-04-09 Harry Odell Improvements in feeding mechanism for embossing and other printing presses
JPS58116498A (ja) 1981-12-28 1983-07-11 Takeda Chem Ind Ltd Il‐2をコードする新規伝令rnaの製造法
DE3377363D1 (en) 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
JPH01196296A (ja) * 1988-01-29 1989-08-08 Toray Ind Inc 動物細胞用発現ベクター
US4919918A (en) 1988-03-14 1990-04-24 Spectrum Consumer Products Co., Inc. Non-alcoholic mouthwash
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
US6221840B1 (en) 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
DE69232619T2 (de) 1991-02-14 2002-09-12 The General Hospital Corp., Charlestown Intestinale kleeblatt-proteine
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9126306D0 (en) 1991-12-11 1992-02-12 Unilever Plc Mouthwash compositions
GB2278358B (en) 1992-02-27 1995-07-26 Lynxvale Ltd Heterologous gene expression in Lactococcus,and the expression products therefrom
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
EP0569604A1 (en) 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5700782A (en) 1993-05-28 1997-12-23 Abbott Laboratories Enteral nutritional product
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
WO1997026855A1 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en) 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
GB2318977B (en) 1996-09-18 1999-07-21 Erling Johansen Compositions
US5869118A (en) 1996-11-13 1999-02-09 Abbott Laboratories Gellan gum to improve physical stability of liquid nutritional products
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
US6171611B1 (en) 1997-11-12 2001-01-09 Dante J. Picciano Iodine-containing nasal moisturizing saline and mouthwash solutions
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE69914932T2 (de) 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
DE60013135D1 (de) 1999-06-30 2004-09-23 Nestle Sa Das lactobacillus delbrueckii lactose operon und deren verwendung zur kontrolle der transkription und/oder expression von gene in bakterienzellen
AU781679B2 (en) 1999-07-05 2005-06-09 Intrexon Actobiotics Nv Delivery of trefoil peptides
AU2001238582A1 (en) * 2000-02-24 2001-09-03 Siga Pharmaceuticals, Inc Intergenic and intragenic integration sites for foreign gene expression in recombinant s. gordonii strains
US7029842B2 (en) * 2000-04-07 2006-04-18 Novozymes A/S Signal sequence trapping
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
JP4347575B2 (ja) 2001-05-03 2009-10-21 アクトジェニックス・エヌブイ 自己自制ラクトコッカス(Loctococcus)株
EP1319410A1 (en) * 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
MXPA05001520A (es) 2002-07-08 2005-05-05 Joe S Wilkins Jr Formulaciones antibacteriales.
WO2004046346A2 (en) 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain
WO2004069177A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
EP1493816A1 (en) * 2003-07-02 2005-01-05 Friesland Brands B.V. Methods and means for regulating gene expression
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
EP1708741B1 (en) 2003-12-24 2016-03-30 Aduro Biotech Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
AU2005227263A1 (en) 2004-03-05 2005-10-06 Novartis Vaccines And Diagnostics, Inc. In vitro test system for predicting patient tolerability of therapeutic agents
US7495092B2 (en) * 2005-01-14 2009-02-24 North Carolina State University Compositions comprising promoter sequences and methods of use
US7764366B2 (en) 2006-07-11 2010-07-27 Besi North America, Inc. Robotic die sorter with optical inspection system
US20100028460A1 (en) * 2006-07-25 2010-02-04 Roland Wolf Improvements in relation to cancer therapy
EP3124614B1 (en) 2007-01-12 2022-06-08 Intrexon Actobiotics NV Lactococcus promoters and uses thereof
WO2010124855A1 (en) 2009-04-30 2010-11-04 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
LT3075745T (lt) 2011-02-10 2018-11-26 Roche Glycart Ag Mutavę interleukino-2 polipeptidai
BR112013023151A2 (pt) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
US9920324B2 (en) 2011-06-01 2018-03-20 Intrexon Actobiotics Nv Polycistronic expression system for bacteria
JP2014526472A (ja) 2011-09-08 2014-10-06 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 免疫応答を調節するための材料および方法
EP3402499B1 (en) 2016-01-14 2021-07-21 Intrexon Actobiotics NV Compositions and methods for the treatment of type 1 diabetes

Also Published As

Publication number Publication date
CN103562390B (zh) 2017-07-18
BR112013030824A2 (pt) 2016-12-06
WO2012164083A1 (en) 2012-12-06
KR20140027405A (ko) 2014-03-06
CA2837634C (en) 2021-12-14
RU2644346C2 (ru) 2018-02-08
AU2012264589A1 (en) 2014-01-09
CN107267546A (zh) 2017-10-20
ES2676877T3 (es) 2018-07-25
HUE039577T2 (hu) 2019-01-28
AU2012264589B2 (en) 2017-02-16
BR112013030824A8 (pt) 2018-04-03
EP2714912A1 (en) 2014-04-09
US20180187203A1 (en) 2018-07-05
HK1244033A1 (zh) 2018-07-27
RU2766157C2 (ru) 2022-02-08
AU2017203281B2 (en) 2019-01-03
CN107267546B (zh) 2021-08-17
EP3360967B1 (en) 2020-09-09
RU2018102374A (ru) 2019-02-21
JP6867866B2 (ja) 2021-05-12
RU2018102374A3 (enExample) 2021-03-30
JP6175428B2 (ja) 2017-08-02
CA2837634A1 (en) 2012-12-06
JP2014518062A (ja) 2014-07-28
CN103562390A (zh) 2014-02-05
US9920324B2 (en) 2018-03-20
CA3136084A1 (en) 2012-12-06
US20210163961A1 (en) 2021-06-03
US10988770B2 (en) 2021-04-27
US20140105863A1 (en) 2014-04-17
EP3360967A1 (en) 2018-08-15
JP2021097671A (ja) 2021-07-01
AU2017203281A1 (en) 2017-06-08
RU2013157300A (ru) 2015-07-20
KR102066292B1 (ko) 2020-01-14
HK1257050A1 (en) 2019-10-11
JP2017200477A (ja) 2017-11-09
EP2714912B1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
AU2017203281B2 (en) Polycistronic expression system for bacteria
JP5584470B2 (ja) ラクトコッカスプロモーター及びその使用
Dieye et al. Ability of Lactococcus lactis to export viral capsid antigens: a crucial step for development of live vaccines
CA2787787A1 (en) Transformation plasmid
US11549115B2 (en) Compositions and methods for regulated gene expression
HK1257050B (en) Polycistronic expression system for bacteria
HK1244033B (zh) 用於细菌的多顺反子表达系统
Chen et al. Genetic operation system of lactic acid bacteria and its applications
WO2018148537A1 (en) Recombinant expression systems and products
HK1227928A1 (en) Lactococcus promoters and uses thereof